Business
Change of public accounting firm
Change of public accounting firm.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nChange of public accounting firm\n \nLONDON and NEW YORK, 25 June 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the appointment of CohnReznick LLP as the Company's US independent registered public accounting firm for the fiscal year ended June 30, 2024.\nOn June 21, 2024, Ernst & Young LLP, was informed of their dismissal as the Company's independent registered public accounting firm with such dismissal to be effective as of June 18, 2024.\n \nJames McCullough, CEO of Renalytix plc, commented: \"We will continue to look for opportunities to improve cost efficiencies and grow revenue as they become available. We are reducing administrative expenses to allocate more resources into sales and marketing, which is proving effective.\"\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nStifel (Nominated Adviser, Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nAlex Price / Nicholas Moore / Nick Harland / Samira Essebiyea\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nInvestec Bank plc (Joint Broker)\n\n\nTel: 020 7597 4000\n\n\n\n\nGary Clarence / Shalin Bhamra\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\nPaul McManus / Alice Woodings /\nCharlotte Edgar\n\n\nTel: 020 7933 8780 or [email protected]\nMob: 07980 541 893 / 07407 804 654 /\n07884 664 686\n\n\n\n\n\n\n\n\n\n\n\n\nCapComm Partners\n\n\n\n\n\n\n\nPeter DeNardo\n\n\nTel: 415-389-6400 or [email protected]\n\n\n\n\n \n \nRenalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.\n \n \n\n","length":8483,"ta...